Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury

Lineage Cell Therapeutics, Inc. announced the clearance, by the FDA, of its Investigational New Drug amendment for OPC1, an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury.